A national key ophthalmic R&D project led by Haohai Biological Technology was launched in Shanghai

On December 2, the launch conference of national key R&D project "Research on a New Type of Intraocular Lens (IOL) and High-end Ophthalmic Implants", led by Haohai Biological Technology and jointly and successfully declared by five institutions including Sun Yat-sen University, Wenzhou Medical University and Sichuan University, was successfully held in Shanghai. Dozens of government representatives, ophthalmic academia representatives, clinicians’ representatives and ophthalmic companies at home and abroad were invited to witness the start-up of the project.

 

As of June 5, 2017, the national key “Biomedical Materials R&D and Rehabilitation and Replacement of Tissue and Organs” intended to set up 18 projects in 2017. There were only 2 declared projects from Shanghai, and “R&D on a New Type of IOL and High-end Ophthalmic Implants” project led by Haohai Biological Technology was one of them, and it had received RMB11.72 million of financial support from the central government.

 

As project leader, Wu Mingxing, a professor from Cataract Treatment Center of Zhongshan Ophthalmic Center of Sun Yat-sen University, made an overall introduction to the National Key R&D project. He pointed out that this R&D project would complete personalized IOL design based on the Chinese people eyes big data and achieved high-end IOL industrialization.

 

Picture: Professor Wu Mingxing making overall presentation for the project

 

At the same time, Professor Wu Mingxing also expressed his high praise for Haohai Biological Technology as the leading unit of the project. He said Haohai Biological Technology had a strong background in the development, production and marketing of IOL, it owned the world’s leading manufacturer of raw materials for IOL such as Contamac in the United Kingdom, as well as international research and development centers and overseas manufacturing centers like Aaren in the United States; and in China, there were domestic old IOL companies, Henan Universe and Zhuhai Eyegood, to provide technical support for product design and production; in addition, it also had the professional marketing team such as Shenzhen NIMO to provide professional market support.

 

Professor Wu Mingxing of cataract treatment center in Zhongshan Ophthalmology Center, Professor Lin Quankui of the Eye Hospital of WMU Zhejiang Hospital, Professor Nie Yu of Engineering Research Center in Biomaterials, Sichuan University, Dr. Hou Yongtai, the Chairman and Executive Director in Haohai Biological Technology, Dr. Wang Liansong of Shenyang Baiao Medical Devices Co., Ltd. respectively introduced contents of the research.

 

Picture: Dr. Hou Yongtai making introduction of the subject

 

Dr. Hou Yongtai pointed out that in order to better improve the layout of the entire ophthalmic industry chain, Haohai Biological Technology pursued the technological innovation of ophthalmology materials, the productive capacity of scientific research achievements transfer, and the safe and effective application of clinical terminals. The subject goal of Haohai Biological Technology was to achieve localization of high-end artificial lens design, processing and production technologies, and establish an IOL production line that meet GMP requirements and enhanced the domestic IOL production capacity.

 

Then, Dr. Wu Jianying, executive director and general manager of Haohai Biological Technology, awarded the plaque for all participating institutions, and Liu Yizhi who was the president of Zhongshan Ophthalmic Center of Sun Yat-sen University and Qu Jia who was the president of The Eye Hospital of Wenzhou Medical University et el., as the project member representatives, accepted the plaque.

 

Picture: Plaque Awarding Ceremony

 

Picture: Signing Ceremony

 

Picture: Group Photo

 

Wu Jianying said, the “R&D of new IOL and high-end ophthalmic implant materials” project was able to stand out from nearly thousands of projects, and was successfully approved and officially launched, which not only had shown the country’s recognition for the innovative and industrial capabilities of the project team led by Haohai Biological Technology, but also further confirmed the company’s confidence and determination that the company would take the field of IOL as the point of penetration, restructure and improve the quality level and market competitiveness of domestic artificial lens, and break through the long-term dependence on import for IOL materials and products.

 

Finally, Yu Shanjiang, director of China National Center for Biotechnology Development of Ministry of Science and Technology, was invited to deliver a speech, saying that the development potential in the field of biotechnology was huge, especially the ophthalmology, with enormous clinical demands. However, there is still a great gap in the clinical dosage and production and R&D capacity of biomedical materials, and the domestic enterprises are expected to accelerate the catch-up pace.

 

Picture: Director Yu Shanjiang giving a speech